← All indications
Ornithine Carbamoyltransferase Deficiency Disease
An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)
Drugs by status
Phase 3 trials (3)
Organizations
Organization Involved with Phase 2 Indications (13)
- Dimension Therapeutics
- Cytonet GmbH & Co. KG
- Children's National Research Institute
- University of Pennsylvania
- University of Pittsburgh
- Case Western Reserve University
- Harvard University
- Stanford University
- University of California, Los Angeles
- Icahn School of Medicine at Mount Sinai
- Children's National Medical Center
- University of Colorado
- Translate Bio, Inc.
Organization Involved with Phase 1 Indications (3)